Kymera Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Kymera Therapeutics Inc KYMR.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of twenty analysts for the quarter was for a loss of 81 cents per share. Wall Street expected results to range from $-1.08 to -31 cents per share.

• Revenue fell 55.3% to $11.48 million from a year ago; analysts expected $23.39 million.

• Kymera Therapeutics Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $76.61 million.

• Kymera Therapeutics Inc shares had fallen by 6.9% this quarter and gained 1.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Kymera Therapeutics Inc is $60.00, about 32.3% above its last closing price of $40.62

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)